相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma
Julie Devin et al.
CANCER RESEARCH (2022)
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
Haiyan Yang et al.
BLOOD ADVANCES (2022)
Ferroptosis: A New Promising Target for Lung Cancer Therapy
Rui Xiong et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
Pin Lu et al.
BLOOD CANCER JOURNAL (2021)
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
Zhiyuan Zhou et al.
ANNALS OF HEMATOLOGY (2021)
High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
Cheng-Chih Tsai et al.
CANCERS (2021)
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
Paolo Strati et al.
HAEMATOLOGICA (2021)
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 Trial
Nitin Jain et al.
JAMA ONCOLOGY (2021)
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Arthur L. Shaffer et al.
BLOOD CANCER DISCOVERY (2021)
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
Victoria M. Smith et al.
HAEMATOLOGICA (2020)
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma
Yang Xia et al.
ACTA HAEMATOLOGICA (2020)
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
Stefano Molica et al.
HEMATOLOGICAL ONCOLOGY (2020)
The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
Anuj K. Sharma et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
Emerging therapies in mantle cell lymphoma
Walter Hanel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Chao Xue et al.
CANCER CELL INTERNATIONAL (2020)
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels
Tobias Roider et al.
NATURE CELL BIOLOGY (2020)
A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas
Daniel P. Larson et al.
JOURNAL OF HEMATOPATHOLOGY (2020)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies
Fabienne Lucas et al.
TARGETED ONCOLOGY (2019)
Targeting BTK in CLL: Beyond Ibrutinib
David A. Bond et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Anne Quinquenel et al.
BLOOD (2019)
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Weiping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Ryan M. Young et al.
IMMUNOLOGICAL REVIEWS (2019)
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium
Andreas Rosenwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Riti Roy et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
Carrie J. Li et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V. Pham et al.
CLINICAL CANCER RESEARCH (2018)
Apoptosis: A Target for Anticancer Therapy
Claire M. Pfeffer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma
Yuko Kinowaki et al.
LABORATORY INVESTIGATION (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways
Giorgio Malpeli et al.
Oncotarget (2018)
Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells
Oreoluwa Adedoyin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
BLOOD (2018)
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
June H. Myklebust et al.
BLOOD (2017)
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
J. Deng et al.
LEUKEMIA (2017)
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
MYC/BCL2/BCL6 triple hit lymphoma: A study of 33 patients who had an aggressive clinical course similar to patients with double hit lymphomas.
Shaoying Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Diffuse large B-cell lymphoma with MYC gene rearrangements Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature
A. V. de Jonge et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death
Min-Young Kwon et al.
ONCOTARGET (2015)
Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas
Chulin Sha et al.
GENOME MEDICINE (2015)
Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model
Bhagwan Yadav et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Trypan blue exclusion assay by flow cytometry
B. A. Avelar-Freitas et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
Regulation of Ferroptotic Cancer Cell Death by GPX4
Wan Seok Yang et al.
CELL (2014)
Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma
Sietse M. Aukema et al.
HAEMATOLOGICA (2014)
Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models
Rachid Skouta et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress
Fatih Uckun et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
Michael Hummel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)